Paul L. Crispen

Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma

Bradley C. Leibovich, Christine M. Lohse, Paul L. Crispen et al. · The Journal of Urology · 2010 · 460 citations

Medicine, Oncology, Surgery +17

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety et al. · The Lancet Oncology · 2020 · 442 citations · Full text

Medicine, Oncology, Urology +13

Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma

Paul L. Crispen, Yuri Sheinin, Timothy J. Roth et al. · Clinical Cancer Research · 2008 · 272 citations

Medicine, Oncology, Pathology +16

T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival

Stephen A. Boorjian, Yuri Sheinin, Paul L. Crispen et al. · Clinical Cancer Research · 2008 · 271 citations · Full text

Life Sciences, Immunology, Oncology +13

Enhancing Renal Masses With Zero Net Growth During Active Surveillance

David A. Kunkle, Paul L. Crispen, David Y.T. Chen et al. · The Journal of Urology · 2007 · 213 citations

Medicine, Oncology, Pathology +16